Know Cancer

or
forgot password

A French, Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)


N/A
18 Years
N/A
Open (Enrolling)
Both
Breakthrough Cancer Pain

Thank you

Trial Information

A French, Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)


Inclusion Criteria:



- Adult (aged ≥18 years) with cancer

- Taking at least 60 mg of oral morphine sulfate or equivalent per day for chronic
background pain

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Satisfaction

Outcome Description:

Satisfaction will be assessed using a 4-point Likert scale.

Outcome Time Frame:

Satisfaction will be assessed approximately 1 hour after each BTPc episode treated with PecFent® from completion of titration through Day 7

Safety Issue:

No

Principal Investigator

Alain Serrie, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Head of Pain Federation - Palliative Medicine Lariboisiere Hospital, Paris France

Authority:

France: Agence Nationale de Sécurité du Médicament et des produits de santé

Study ID:

CP057/11

NCT ID:

NCT01693328

Start Date:

September 2012

Completion Date:

Related Keywords:

  • Breakthrough Cancer Pain
  • quality of life
  • PecFent
  • Lazanda
  • fentanyl
  • intranasal
  • breakthrough cancer pain

Name

Location